✦ LIBER ✦

Efficacy and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Kidney Transplant Recipients

✍ Scribed by Tojimbara, T.; Nakajima, I.; Yashima, J.; Fuchinoue, S.; Teraoka, S.

Book ID: 122128865
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 203 KB
Volume: 46
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2013.09.045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Febuxostat: A Selective Xanthine Oxidase

Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout

✍ Bruce, S. P 📂 Article 📅 2006 🏛 Harvey Whitney Books Company 🌐 English ⚖ 150 KB

The Effect of Age and Gender on Pharmaco

The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

✍ Khosravan, Reza; Kukulka, Michael J.; Wu, Jing-Tao; Joseph-Ridge, Nancy; Vernill 📂 Article 📅 2008 🏛 Sage Publications 🌐 English ⚖ 222 KB

Febuxostat: A selective xanthine-oxidase

Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout

✍ Michael E. Ernst; Michelle A. Fravel 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 178 KB

The Effect of Mild and Moderate Hepatic

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

✍ Khosravan, Reza; Grabowski, Brian A.; Mayer, Michael D.; Wu, Jing-Tao; Joseph-Ri 📂 Article 📅 2006 🏛 Sage Publications 🌐 English ⚖ 239 KB

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal

Safety and efficacy of basiliximab for t

Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients

✍ M.H Shah; M.Z.M Bokhari; M.T.M Bokhari; A Farooq; S.M Yousaf 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 57 KB